Cataloguenumber
ANT-154
Introduction
Heparanaseisanendo-β-D-glucuronidase,whichdegradesheparansulfatesidechainsofheparansulfateproteoglycans(HSPGs)intheextracellularmatrix.HeparanaseplaysanimportantroleinECMdegradation,facilitatingthemigrationandextravasationoftumorcellsandinflammatoryleukocytes(1,2,3).Upondegradation,heparanasereleasesgrowthfactorsandcytokinesthatstimulatecellproliferationandchemotaxis(4,5).Heparanaseisaheterodimercomprisedofa50kDasubunitharboringtheactivesiteanda8kDasubunit.Itisproducedasalatent65kDaprecursorandproteolyticallyprocessedtoitsactiveform(1,6).Heparanaseishighlyexpressedinmyeloidleukocytes(i.e.neutrophils)inplateletsandinhumanplacenta.Humanheparanasewasfoundtobeupregulatedinvarioustypesofprimarytumors,correlatinginsomecaseswithincreasedtumorinvasivenessandvascularityandwithpoorProspectivesurvival(7,8).
Source
MabHP3/17isaProteinGaffinitypurifiedmonoclonalantibodyraisedagainstapolypeptidefromthe50kDasubunitofHeparanase.
IgSubclass
MouseIgG2Bκ
Formulation
Eachvialcontains50,100or150μgin12.5,25or37.5μlrespectively,of0.22micronfilteredsolutionof20mMSodiumPhosphate;150mMNaCl;pH7.2,containing0.01%Thimerosal.
Applications
Westernblot
Immunohistochemistry
Specificity
HP3/17reactswiththe50kDasubunitandwiththe65kDaprecursorofhumanormouseHeparanasebyWesternblottingandimmunohistochemistry.
RecommendeddilutionrangeforWesternblotanalysis:1:4000.
Recommendeddilutionrangeforimmunohistochemistry:1:40.
Purity
>98%onSDS-PAGEwhenloaded50μg/lane.
StABIlity
Storeat4°C.Stableforsixmonthsfromthedateofshipment.Forextendedstorage,freezeinworkingaliquotsat-20°C.Avoidrepeatedfreeze-thawcycles.
PatentProtectedCountries
Anti-heparanaseantibodiesandtheiruses,includingHP3/17anditsuses,areprotectedbyUS.PatentsNo.6,177,545;6,531,129,additionalUSpatentapplicationsandpatentsandpatentapplicationsworldwide.
References
1.I.Vlodavsky,Y.Friedmann,M.Elkin,H.Aingorn,R.Atzmon,R.Ishai-Michaeli,M.Bitan,O.Pappo,T.Peretz,I.Michal,L.Spector,I.Pecker.1999.Mammalianheparanase:genecloning,expressionandfunctionintumorprogressionandmetastasis.Nat.Med.5:793–802.
2.I.Vlodavsky,Y.Friedman.2001.Molecularpropertiesandinvolvementofheparanaseincancermetastasisandangiogenesis.J.Clin.Invest.108:341–347.
3.C.R.Parish,C.Freeman,M.D.Hulett.2001.Heparanase:akeyenzymeinvolvedincellinvasion.Biochem.Biophys.Acta1471:M99–M108.
4.I.Vlodasvsky,G.Korner,R.Ishai-Michaeli,P.Bashkin,R.Bar-Shavit,Z.Fuks,1990.Extracellularmatrix-residentgrowthfactorsandenzyme:PossIBLeinvolvementintumormetastasisandangiogenesis.CancerMetastasisRev.9:203-226.
5.P.Bashkin,S.Doctrow,M.Klagsbrun,C.M.Svahn,J.Folkman,I.Vlodavsky.1989.Basicfibroblastgrowthfactorbindstosubendothelialextracellularmatrixandisreleasedbyheparitinaseandheparin-likemolecules.Biochemistry28:1737-1743.
6.M.B.Fairbanks,A.M.Mildner,J.W.Leone,G.S.Cavey,W.R.Mathews,R.F.Drong,J.L.Slightom,M.J.Bienkowski,C.W.Smith,C.A.Bannow,R.L.Heinrikson.1999.Processingofthehumanheparanaseprecursorandevidencethattheactiveenzymeisaheterodimer.J.Biol.Chem.274:29587–29590.
7.A.Koliopanos,H.Friess,J.Klee.,X.Shi,Q.Liao,I.Pecker,I.Vlodavsky,A.Zimmermann,M.W.Buchler.1992.Heparanaseexpressioninprimaryandmetastaticpancreaticcancer.CancerRes.61:4655–4659.
8.K.Gohji,H.Hirano,M.Okamoto,S.Kitazawa,M.Toyoshima,J.Dong,Y.Katsuoka,M.Nakajima.2001.Expressionofthreeextracellularmatrixdegradativeenzymesinbladdercancer.Int.J.Cancer95:295–301.
DataSheet
ToviewtheFULLVERSION clickHere:
Usage
ProSpec"sproductsarefurnishedforLABORATORYRESEARCHUSEONLY.Theproductmaynotbeusedasdrugs,agriculturalorpesticidalproducts,foodadditivesorhouseholdchemicals.
